✦ LIBER ✦

Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease

✍ Scribed by Mehmet Arslan; Russell H. Wiesner; Corey Sievers; Kathleen Egan; Nizar N. Zein

Book ID: 111723010
Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 177 KB
Volume: 7
Category: Article
ISSN: 1527-6465
DOI: 10.1053/jlts.2001.23069

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antibody Response to Hepatitis B Vaccine

Antibody Response to Hepatitis B Vaccine in End-stage Renal Disease Patients

✍ KM Chow; MC Law; CB Leung; CC Szeto; PKT Li 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Famciclovir treatment of hepatitis B inf

Famciclovir treatment of hepatitis B infection in patients with end-stage liver disease

✍ M. Manns; P. Neuhaus; H. Schoenborn; K.E. Griffin 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 171 KB

Conversion rates of patients receiving h

Conversion rates of patients receiving hepatitis A vaccination with end stage liver disease awaiting liver transplantation

✍ Smallwood, Gregory A.; Coloura, Christina T.; De Vera, Michael E.; Martinez, Enr 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 343 KB

Management of End-Stage Liver Disease in

Management of End-Stage Liver Disease in Chronic Hepatitis B

✍ Tan, Hui-Hui; Martin, Paul 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 134 KB

Vaccination against hepatitis b in patie

Vaccination against hepatitis b in patients with chronic liver disease

✍ Gary Reiss; Emmet B. Keeffe 📂 Article 📅 2006 🏛 Current Science Inc. 🌐 English ⚖ 200 KB

Hepatitis B vaccination of patients with

Hepatitis B vaccination of patients with chronic liver disease

✍ Keeffe, Emmet B. ;Krause, David S. 📂 Article 📅 1998 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 29 KB 👁 1 views

De novo hepatitis B infection after liver transplantation, in spite of its low prevalence as found by Fabia et al, 1 is of major concern, especially for infected patients and their families. More follow-up time is needed to assess the real impact in morbidity, mortality, and economic costs. Althoug